This study included 44 patients enrolled at the University of Tanta in Egypt, where genotype 4 is the predominant HCV type. Almost all (40 patients) had genotype 4, but 3 had genotype 1, and 1 had genotype 2.
Yes...but the sample size was small, only 3 G1, 1 G2. Still 100% is 100% and good!
This was one of the studies I used to make my decision to add Alinia to my tx. I had the eairlier report of this trail, that did not yet include SVR info, only EOT, as well as the one released in Boston last year. DID ANYONE NOTICE THAT THE 4 WEEK LEAD_IN ARM WAS----ribavironLESS!!!!!!!!---Alinia and Peg ONLY with a 80% SVR rate. WAKE UP folks this stuff is SOMETHING that deserves more attention. I know this arm only had 44 patients but STILL!! Every time someone joins the forum saying "I just started txing, 1wk ago, 1 month ago, 1 day, whatever I cringe. NO WAY I WOULD NOT ADD ALINIA TO SOC knowing what we know today. jerry
The problem for Romark is that Alinia has already entered the market as a standard antidiarrheal drug used around the world. So, they can't control the price / limit the application to Hep C now. While the extra sales are good news for them, the drug would have made a lot more money if it had been witheld from other applications, with an inflated price for Hep C patients. I have no doubt that the new Hep C specific treatments will be very expensive by contrast.
Good and bad news for us. Any new drugs coming onto the market now will not only have to prove to be effective, but will also have to prove they are more effective than Alinia, otherwise people will choose the "cheap" Alinia, not the expensive Veretex, or whatever else. The bad news is that this then represents an extra economic hurdle for any Hep C drugs in development, so some of them may be more likely to be pulled out of trials.
one thing that impressed me re: the original study was HR's discussion with the Eyptian doc afterthe lecture. Even though he used primarily the immigrant uninsured populace for his study he kept very close tabs on their meds compliance.
I believe that entire discussion and HR's take is on Gauf's homepage journal.
"These data indicate that when using nitazoxanide, ribavirin (which helps prevent relapse) may not be needed to maintain a sustained response, suggested Romark Chief Medical Officer and study co-investigator Emmet Keeffe."
Wow, imagine if this pans out! Tox would be soooo much more tolerable.
It would be fantastic if Riba was eliminated. I had mono therapy in acute stage, and found it to be extremly mild treatment in comparsion to combo therapy. The removal of Riba, if possible, will make the lives of all people treating much much better.
Copyright 1994-2016 MedHelp International. All rights reserved.
MedHelp is a division of Aptus Health.
This site complies with the HONcode standard for trustworthy health information.
The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.